The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are:
* How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion.
* Describe the safety of veverimer based on changes in serum bicarbonate and potassium.
* Assess the changes in bone resorption.
* Assess the changes in bone formation.
* Explore the effect of veverimer on physical performance.
Participants will:
* Take veverimer or placebo every day or every other day for 8 weeks
* Visit the clinic a total of 8 times (including screening) for checkups and testing
* Keep a medication diary tracking each day they take the study drug

开始日期2026-03-01

申办/合作机构

Tufts Medical Center, Inc.

NCT07355062

/ Recruiting临床3期

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)

The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.

开始日期2026-01-13

申办/合作机构

Renibus Therapeutics, Inc.

NCT03710291

/ Terminated临床3期

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

The purpose of this study is to evaluate the effect of TRC101 on the progression of chronic kidney disease (CKD) and to evaluate the safety profile of TRC101 in CKD patients with metabolic acidosis.

开始日期2018-11-20

申办/合作机构

Tricida, Inc.

100 项与 Veverimer 相关的临床结果

登录后查看更多信息

100 项与 Veverimer 相关的转化医学

登录后查看更多信息

100 项与 Veverimer 相关的专利（医药）

登录后查看更多信息

项与 Veverimer 相关的文献（医药）

2025-05-01·Kidney360

Veverimer, a Nonabsorbed Gastrointestinal Tract HCl Binder, Decreases Renal Ammoniagenesis and Mitigates Nephrotoxic Serum Nephritis

Article

作者: Johnson, Ali C.M. ; Zager, Richard A.

Key Points:

Veverimer, a nonabsorbed gastrointestinal tract HCl binder, increases bicarbonate generation, causes bicarbonaturia, and thus decreases renal ammoniagenesis.Decreases in ammoniagenesis can suppress kidney disease–induced alternative complement pathway activation.As a result of the above changes, decreases in renal injury, as induced by nephrotoxic serum injection, can occur.

Background:

Increased tubular ammoniagenesis is an adaptive response to progressive kidney disease, facilitating net acid excretion. However, excess ammonia production can also exacerbate kidney disease progression, in part, by activating the alternative complement cascade. Oral Na bicarbonate therapy can decrease the systemic H+ burden, limiting ammonia production. However, poor compliance limits bicarbonate's efficacy. Veverimer is an oral, Na+-free, nonabsorbed polymer that binds H+ within the gastrointestinal (GI) tract. This stimulates GI carbonic anhydrase-mediated bicarbonate production and systemic bicarbonate uptake. Hence, the goals of this study were to test whether GI HCl binding decreases renal tubular ammoniagenesis, to assess whether complement activation decreases, and to determine whether these changes can mitigate nephrotoxic serum (NTS) nephritis, in which complement activation may play a role.

Methods:

A normal diet± veverimer (4.5% w/w) was fed to normal mice for approximately 1 week. Veverimer's effect on plasma bicarbonate; blood/urinary pH; urinary ammonia excretion; and tubular H+ transporter, NHE3, density was assessed. Additional mice were fed the normal or veverimer diet after NTS injection. Urine protein, albumin, ammonia, C5b-9 excretion, and plasma C3a levels were measured 1 week and/or 2 weeks after NTS injection. Renal histologic changes (hematoxylin and eosin stain; C5b-9, CD45 immunohistochemistry), and selected injury mediators/biomarkers (NGAL, IL-6, MCP-1, TGFβ1, and endothelin-1 mRNAs) were also assessed.

Results:

Veverimer increased plasma bicarbonate/urinary pH, reduced urinary ammonia, and decreased NHE3 in normal mice. Veverimer also reduced NTS-induced proteinuria/albuminuria, urinary ammonia, and C5b-9 excretion (by approximately 60%, 75%, and 50%, respectively). Significant reductions in NTS-induced glomerular/tubulointerstitial injury, inflammatory/profibrotic gene expression, renal C5b-9 deposition, and suppressed plasma C3a levels were observed. Oral bicarbonate also conferred protection, implicating bicarbonate's role in veverimer's beneficial effect.

Conclusions:

Veverimer-mediated bicarbonate generation can suppress renal ammoniagenesis and complement activation. These findings suggest a potential benefit of veverimer/bicarbonate therapy in selected complement-mediated kidney diseases.

2024-03-01·Journal of the American Society of Nephrology : JASN

VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

Article

作者: Wesson, Donald E ; Navdeep Tangri ; Parsell, Dawn ; Gerrit Klaerner ; Li, Elizabeth ; Tangri, Navdeep ; Vlado Perkovic ; Vandana S. Mathur ; Klaerner, Gerrit ; Donald E. Wesson ; Perkovic, Vlado ; Wheeler, David C ; David C. Wheeler ; David A. Bushinsky ; Michael Walker ; Bushinsky, David A ; Stasiv, Yuri ; Elizabeth Li ; Lesley A. Inker ; Mathur, Vandana S ; Yuri Stasiv ; Inker, Lesley A ; Walker, Michael ; Dawn Parsell

Significance Statement:

Metabolic acidosis is a common complication of CKD and is associated with more rapid decline of kidney function, but well-powered controlled randomized trials testing the effect of treating metabolic acidosis on slowing CKD progression have not been conducted. The VALOR-CKD study randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or veverimer (a novel hydrochloric acid binder). The findings did not demonstrate the efficacy of veverimer in slowing CKD progression, but the difference in serum bicarbonate between placebo and drug arms was only approximately 1 mEq/L. Veverimer was safe and well tolerated.

Background:

Metabolic acidosis is common in CKD, but whether its treatment slows CKD progression is unknown. Veverimer, a novel hydrochloric acid binder that removes acid from the gastrointestinal tract, leads to an increase in serum bicarbonate.

Methods:

In a phase 3, double-blind, placebo-controlled trial, patients with CKD (eGFR of 20–40 ml/min per 1.73 m2) and metabolic acidosis (serum bicarbonate of 12–20 mEq/L) from 35 countries were randomized to veverimer or placebo. The primary outcome was the composite end point of CKD progression, defined as the development of ESKD (kidney transplantation or maintenance dialysis), a sustained decline in eGFR of ≥40% from baseline, or death due to kidney failure.

Results:

The mean (±SD) baseline eGFR was 29.2±6.3 ml/min per 1.73 m2, and serum bicarbonate was 17.5±1.4 mEq/L; this increased to 23.4±2.0 mEq/L after the active treatment run-in. After randomized withdrawal, the mean serum bicarbonate was 22.0±3.0 mEq/L and 20.9±3.3 mEq/L in the veverimer and placebo groups at month 3, and this approximately 1 mEq/L difference remained stable for the first 24 months. A primary end point event occurred in 149/741 and 148/739 patients in the veverimer and placebo groups, respectively (hazard ratio, 0.99; 95% confidence interval, 0.8 to 1.2; P = 0.90). Serious and overall adverse event incidence did not differ between the groups.

Conclusions:

Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression. The lower than expected bicarbonate separation may have hindered the ability to test the hypothesis.

Clinical Trial registry name and registration number:

VALOR-CKD, NCT03710291.

2023-05-31·Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Article

作者: Bushinsky, David A ; Wheeler, David C ; Perkovic, Vlado ; Wesson, Donald E ; Parsell, Dawn ; Stasiv, Yuri ; Walker, Michael ; Tangri, Navdeep ; Li, Elizabeth ; Inker, Lesley ; Mathur, Vandana S ; Klaerner, Gerrit

ABSTRACT:

Background:

Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established. Veverimer is a novel hydrochloric acid binder that removes acid from the gastrointestinal tract leading to an increase in serum bicarbonate; it is being developed to treat metabolic acidosis with the goal of slowing progression of CKD.

Methods:

The VALOR-CKD trial is an international, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate the effect of once-daily veverimer on kidney disease progression in patients with metabolic acidosis and CKD. Eligibility criteria include a serum bicarbonate in the range of 12–20 mmol/L and an estimated glomerular filtration rate (eGFR) of 20–40 mL/min/1.73 m2. The primary outcome is kidney disease progression defined as the development of end-stage kidney disease, a sustained decline in eGFR of >40% from baseline or death due to kidney failure. Key secondary endpoints include effects on physical function.

Results:

Between December 2018 and December 2021, 1480 participants were randomized. The mean age at baseline was 65.1 years and 42% of the patients were female. The mean baseline eGFR was 29.1 mL/min/1.73 m2 and mean serum bicarbonate was 17.5 mmol/L. The median urine albumin-to-creatinine ratio at screening was 201 mg/g and the median 5-year predicted risk of kidney failure was 32%. Diabetes and hypertension were present in 56% and 98% of participants, respectively.

Conclusions:

VALOR-CKD has recruited a large population of people with metabolic acidosis at high risk for CKD progression to determine the effects of veverimer on the risk of progressive loss of kidney function.

项与 Veverimer 相关的新闻（医药）

2026-02-19

·PRNewswire

Renibus Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference

SOUTHLAKE, Texas, Feb. 19, 2026 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation in the 36th Annual Oppenheimer Life Sciences Conference, taking place February 25-26, 2026. Bhupinder Singh, MD, FASN, FNKF, Chief Medical Officer of Renibus, will present virtually on Wednesday, February 25, 2026 at 2:40pm Eastern Standard Time. Company management will also meet with investors in one-on-one meetings during the conference. About Renibus Therapeutics Renibus Therapeutics® is a clinical late-stage biopharmaceutical company focused on the prevention and treatment of cardiac, renal, and metabolic diseases. Renibus' lead program, veverimer, is currently in Phase 3 development for the treatment of metabolic acidosis in adults with chronic kidney disease. The Company's second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial evaluating RBT-1 in patients undergoing cardiac surgery. Results from this trial suggest that further development in risk-enriched patients may be warranted and is currently under evaluation. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics 21% more press release views with Request a Demo

临床3期

2025-06-10

·PRNewswire

Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)

SOUTHLAKE, Texas, June 10, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane. "Ultra-rare life-threatening conditions, including anti-GBM and several other forms of glomerular and tubulointerstitial kidney diseases, can be aggressive and challenging to treat effectively with current therapies," said Bhupinder Singh M.D., Chief Medical Officer of Renibus. "This Orphan Drug Designation further underscores the potential of veverimer to offer a significant advantage beyond drugs currently used to treat kidney disease, and we look forward to advancing this asset in the clinic." The Orphan Drug Designation program is intended to encourage the development of products for diseases that affect fewer than 200,000 individuals in the United States. With this designation Renibus is eligible for certain incentives, such as tax credits for clinical trials, exemption from user fees, and a potential 7 years of market exclusivity upon approval. Richard Zager, Senior Vice President of Translational Research of Renibus, commented, "Veverimer markedly suppresses ammoniagenisis and associated activation of the complement cascade, which are key mediators of anti-GBM disease and other complement mediated renal diseases. We are continuing to evaluate the potential of veverimer to address these diseases of high unmet medical need." About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' lead first-in class combination drug therapy is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. RBT-1 has just completed enrollment in a Phase 3 pivotal trial (called PROTECT) measuring its primary objective to reduce the risk of post operative complications and improve outcomes following cardiac surgery. The drug has been granted FDA Breakthrough and Fast Track Designations by the Division of Cardiology and Nephrology at the FDA. Veverimer is an oral, non-absorbed hydrochloric acid binder that has been granted Orphan Drug Designation for the treatment of anti-glomerular basement membrane disease. Renibus is also evaluating veverimer's potential use for the treatment of other renal diseases. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药快速通道临床3期

2025-04-25

·PRNewswire

Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)

- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that a poster presentation will be delivered on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA), taking place April 26-29, 2025 in Montreal. RBT-1 is a single-dose, first-in-class, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus previously completed a Phase 2 study of RBT-1 (NCT04564833) in February 2023, announced positive final results from this study in May 2023, and has recently completed enrollment in its Phase 3 PROTECT study. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Our poster highlights the complicated economic impact of post-operative complications and increasing costs for CABG and value surgery to the healthcare system, which directly affects anesthesiologists. With the use of RBT-1 in our Phase 2 study, we reduced the complication rates from cardiovascular surgery, and in turn, the overall healthcare costs. We look forward to continuing to demonstrate these encouraging results in Phase 3." Frans van Wagenberg, MD, Huntsville Heart Center, Huntsville, Alabama, commented, "I am pleased to present results of a cost-analysis based on a Phase 2 trial which suggest that RBT-1 has a protective effect, leading to lower complication rates and reduced average expected costs overall. Additional data from an ongoing Phase 3 trial, which includes a 1-year post-discharge follow-up, will further evaluate the impact of RBT-1 on clinical, economic, and qualitative outcomes compared to standard care." Details of the poster presentation at SCA 2025: Title: "Clinical and Economic Impact of RBT-1 on Post-operative Complications and Costs for CABG and Valve Surgery" Date and Time: Sunday, April 27, 2025 at 12:30 Authors: Frans van Wagenberg, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhDc, Raf Magar MB About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently being evaluated in the Phase 3 PROTECT study for its lead indication to reduce post-operative complications following cardiothoracic surgery. Previously, Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study and announced completion of enrollment in April 2025. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial (called PROTECT) to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. The drug has received FDA Orphan Drug Designation. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道临床2期孤儿药突破性疗法

100 项与 Veverimer 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
酸中毒	申请上市	美国	Tricida, Inc.	2019-09-04
慢性肾病	临床3期	美国	Tricida, Inc.	2017-12-20
慢性肾病	临床3期	保加利亚	Tricida, Inc.	2017-12-20
慢性肾病	临床3期	匈牙利	Tricida, Inc.	2017-12-20
慢性肾病	临床3期	塞尔维亚	Tricida, Inc.	2017-12-20
慢性肾病	临床3期	斯洛文尼亚	Tricida, Inc.	2017-12-20
慢性肾病	临床3期	乌克兰	Tricida, Inc.	2017-12-20
代谢性骨病	临床1期	美国	Tufts Medical Center, Inc.	2026-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03710291 (VALOR-CKD, Pubmed \| NEWS 1 \| NEWS 2)	-	-	1,480	Veverimer	夢艱壓構襯艱積繭艱鹽(鹹鹹顧窪憲繭廠遞壓膚) = 夢獵憲繭壓夢製簾廠艱積繭糧夢獵壓蓋襯壓憲 (築獵糧醖淵願膚廠鏇鑰 )	不佳	2022-10-24
				安慰剂	夢艱壓構襯艱積繭艱鹽(鹹鹹顧窪憲繭廠遞壓膚) = 積醖網餘鬱鏇壓鏇蓋範積繭糧夢獵壓蓋襯壓憲 (築獵糧醖淵願膚廠鏇鑰 )
NCT03390842 (Pubmed) 人工标引	临床3期	酸中毒 \| 慢性肾病	77	Veverimer	膚網遞鬱餘網壓積衊獵(觸糧願餘願鑰鹹廠蓋繭): P-Value = 0.0002 更多	积极	2022-02-25
				Placebo
NCT03390842 (CTgov)	临床3期	酸中毒 \| 慢性肾病	196	TRC101 (TRC101 Treatment Arm)	襯範顧願衊觸壓淵鏇廠 = 壓壓鑰壓淵鏇餘壓顧膚襯築遞廠鏇願鬱憲鑰淵 (鑰憲顧構鏇廠餘餘夢鹹, 蓋鹽網願淵糧壓壓齋範 ~ 窪窪繭遞淵製網獵醖艱) 更多	-	2021-10-22
				Placebo (Placebo Treatment Arm)	襯範顧願衊觸壓淵鏇廠 = 壓鏇選遞製夢襯齋鹹廠襯築遞廠鏇願鬱憲鑰淵 (鑰憲顧構鏇廠餘餘夢鹹, 夢繭蓋鏇夢鹽廠顧夢齋 ~ 衊蓋夢獵網積醖醖鬱繭) 更多
NCT03317444 (CTgov)	临床3期	酸中毒	217	TRC101 (TRC101 Treatment Arm)	願糧襯淵夢構窪壓窪齋 = 憲齋獵蓋艱製襯餘鬱積鏇鹹齋簾積壓積築齋窪 (獵願壓鹹願襯築鹽願築, 鹽夢鬱餘鑰衊衊廠製夢 ~ 選壓醖蓋醖憲鏇齋遞網) 更多	-	2021-04-26
				Placebo (Placebo Treatment Arm)	願糧襯淵夢構窪壓窪齋 = 製艱夢蓋網鏇襯積製醖鏇鹹齋簾積壓積築齋窪 (獵願壓鹹願襯築鹽願築, 範糧糧遞夢簾製鹹醖淵 ~ 鹹築願窪膚鹽糧鹽餘淵) 更多
ASN2020	临床3期	酸中毒 \| 慢性肾病	193	Veverimer	選夢觸遞餘廠壓衊襯糧(獵壓壓齋襯窪鹽艱遞構) = 繭範憲鑰鹽憲鑰鏇獵遞餘願艱觸廠積醖選鑰獵 (築窪鏇夢願網齋鏇獵願 )	积极	2020-10-19
Phase 3 randomized, blinded, placebo-controlled trials (ASN2020)	临床3期	慢性肾病	217	Veverimer	觸窪繭蓋鏇壓淵鏇糧觸(膚蓋鹽獵鬱製衊鑰觸製) = 餘蓋齋顧觸齋願簾鬱選鹹選網艱膚鬱壓鬱積襯 (構糧網衊餘獵簾獵範夢 )	积极	2020-10-19
ASN2020	临床3期	-	217	Veverimer	範鹽積遞醖顧窪構鬱願(鹹遞艱願窪膚繭願淵襯) = improved both KDQOL-PFD scores and RCS time 鹽積積積鏇鑰遞繭構艱 (鑰膚獵蓋觸艱窪艱鹹鏇 ) 更多	积极	2020-10-19
ASN2020	临床3期	糖尿病 \| 慢性肾病	196	Veverimer	選鹽願襯顧製簾襯憲繭(獵壓鑰醖鏇衊獵製顧獵) = significantly improved in the veverimer group (+12.5 v +0.3, P <0.001) 遞艱簾鹽鑰鏇廠齋築構 (築繭餘衊繭積鏇餘醖膚 )	积极	2020-10-19
ASN2020	临床1期	-	46	Veverimer	衊範鑰窪襯網壓觸鹽獵(積遞構鹹蓋襯獵蓋淵製) = 糧糧鬱糧顧構齋鏇製窪鬱廠範鏇淵簾網鹽願鬱 (獵願襯醖繭夢憲鹹餘繭 )	积极	2020-10-19
				Omeprazole	衊範鑰窪襯網壓觸鹽獵(積遞構鹹蓋襯獵蓋淵製) = 憲獵壓醖窪糧選壓憲範鬱廠範鏇淵簾網鹽願鬱 (獵願襯醖繭夢憲鹹餘繭 )
ERA2020	临床3期	慢性肾病	196	Veverimer	膚壓衊壓壓襯襯醖獵壓(鬱觸夢齋選獵積艱鏇築) = 餘夢繭觸構糧網憲鑰醖憲鑰醖簾選顧鏇鏇網簾 (遞衊蓋築糧築鹽願鑰願 ) 更多	积极	2020-06-06
				Placebo	膚壓衊壓壓襯襯醖獵壓(鬱觸夢齋選獵積艱鏇築) = 範製窪淵選獵蓋積獵製憲鑰醖簾選顧鏇鏇網簾 (遞衊蓋築糧築鹽願鑰願 )